US 11,752,468 B2
Materials and methods for producing blood products
Joshua Donald Montgomery, Silver Spring, MD (US); Braden Carl Ishler, Montgomery Village, MD (US); Stephen Edward Amos, Buckeystown, MD (US); Keith Andrew Moskowitz, Westfield, IN (US); Amber Nicole Lee, Montgomery Village, MD (US); Rafael Jorda, Merignac (FR); Glen Michael Fitzpatrick, North Potomac, MD (US); and Michael Alexander Mathews, Arlington, VA (US)
Assigned to Cellphire, Inc., Rockville, MD (US)
Filed by Cellphire, Inc., Rockville, MD (US)
Filed on Nov. 16, 2022, as Appl. No. 18/56,220.
Application 18/056,220 is a continuation of application No. 16/865,215, filed on May 1, 2020, granted, now 11,529,587.
Claims priority of provisional application 62/936,122, filed on Nov. 15, 2019.
Claims priority of provisional application 62/843,061, filed on May 3, 2019.
Prior Publication US 2023/0226493 A1, Jul. 20, 2023
Int. Cl. B01D 61/14 (2006.01); C12N 5/078 (2010.01); A01N 1/00 (2006.01)
CPC B01D 61/14 (2013.01) [C12N 5/0644 (2013.01); B01D 2311/12 (2013.01); B01D 2315/10 (2013.01); B01D 2315/16 (2013.01)] 25 Claims
OG exemplary drawing
1. A process for preparing a thermally-treated platelet composition, the process comprising:
performing tangential flow filtration (TFF) of a platelet composition comprising platelets in a preparation agent comprising a buffering agent, between 10 mM and 1000 mM of saccharides comprising a monosaccharide and/or a disaccharide, and polysucrose in an amount in the range of 3% to 7%, wherein the TFF is performed until a particular residual plasma protein endpoint is reached, thereby preparing a TFF-treated composition comprising at least 1000×103 platelets/μl in an aqueous medium having less than or equal to 15% plasma protein and having less than 5.0% microparticles by scattering intensity;
freeze drying the TFF-treated composition comprising platelets in the aqueous medium to form a freeze-dried platelet composition; and
heating the freeze-dried platelet composition at a temperature in the range of 60° C. to 85° C. for at least 1 hour to not more than 36 hours to thermally treat the freeze-dried platelets in the freeze-dried platelet composition to form the thermally-treated platelet composition,
wherein the thermally-treated platelets in the thermally-treated platelet composition are capable of generating thrombin in an in vitro thrombin formation assay.